A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm Study to Investigate the Efficacy and Safety of Adjunctive Treatment With Brenipatide in Delaying Time to Relapse Compared With Placebo in Adult Participants With Major Depressive Disorder (RENEW-MDD 1)
Latest Information Update: 23 Feb 2026
At a glance
- Drugs Brenipatide (Primary)
- Indications Major depressive disorder
- Focus Registrational; Therapeutic Use
- Acronyms RENEW-MDD-1
- Sponsors Eli Lilly and Company
Most Recent Events
- 23 Feb 2026 New trial record